The Company reported a net loss of approximately $8.4 million, or $0.25 per share, for the three months ended September 30, ...

Women's health innovator Evofem Biosciences, Inc. ("Evofem" or "the Company") today announced financial results for the third quarter and nine-month period ended September 30, 2024. Highlights ...

Announced promising safety and positive biomarker data from Cohort 2 (5mg BID) of the Phase 1b clinical trial of LTI-03 in idiopathic pulmonary fibrosis (IPF) patients demonstrating dose dependent ...

United Therapeutics' pipeline and Tyvaso DPI drive strong growth. Read why UTHR stock offers substantial upside with ...

Plus: How AI can make it easier to find drugs from nature and a study suggests Ozempic could treat alcoholism.

Premature shortening of these sequences is also the cause of genetic diseases (or telomeropathies) such as Dyskeratosis ...

While PAH can occur due to unknow reasons (what physicians call idiopathic), some common causes include: Connective tissue ...

Financially, Gyre had cash and cash equivalents totaling $15.9 million as of September 30, 2024. For the third quarter of ...

On Wednesday, Aileron Therapeutics Inc (NASDAQ; ALRN) revealed topline data from Cohort 2 of its Phase 1b trial of safety and ...

Sino-American firm Insilico Medicine has shown the potential not just of its pipeline and lead candidate by presenting ...